慢性疼痛亚型的分类和导致心力衰竭的生物标志物
Asa B Smith1, Jamie Rausch1, Fletcher A White2
1School of Nursing, Indiana University, Indianapolis, IN.
European journal of cardiovascular nursing
|February 11, 2026
概括
患有心力衰竭的成年人经历了常见的慢性疼痛,混合疼痛亚型显示出更高的严重程度. 在这项试点研究中,较低的互白素-10和互白素-33水平与疼痛严重程度的增加有关.
科学领域:
- 心脏病学 心脏病学
- 疼痛医学 医学 疼痛医学
- 免疫学 免疫学 免疫学
背景情况:
- 慢性疼痛在心力衰竭 (HF) 患者中很普遍,但疼痛亚型和相关生物标志物仍未得到充分研究.
- 了解这些因素对于开发针对性疼痛管理策略至关重要.
研究的目的:
- 描述慢性疼痛的严重程度,神经病痛的质量,位置和亚型,在成年人中HF.
- 为了比较不同疼痛亚型的疼痛严重程度和生物标志物水平.
- 探索生物标志物水平与疼痛严重程度之间的相关性.
主要方法:
- 一项试点描述性研究分析了来自60名患有HF和慢性疼痛的成年人的横截面数据.
- 通过使用PainDETECT问卷来评估疼痛.
- 血液生物标志物包括IL-10,IL-18,IL-1β,IL-33,IL-6,IL-8,瘤坏死因子 (TNF) -α,来自大脑的神经营养因子,莱普,阿迪波涅克丁和C反应蛋白被测量.
主要成果:
- 大多数参与者 (73.3%) 仅报告了感觉性疼痛,较少的人报告神经病变性疼痛 (6.7%) 或混合性疼痛 (20.0%).
- 混合疼痛亚型呈现出最高的当前和4周平均疼痛严重程度得分.
- 虽然没有生物标志物在疼痛亚型之间有显著差异,但较低的IL-10 (p=.049) 和IL-33 (p=.014) 水平与更大的疼痛严重程度有关.
结论:
- 这项研究描述了慢性疼痛表型及其与心力衰竭患者特定生物标志物的相关性.
- 这些发现表明IL-10和IL-33在疼痛严重程度方面的潜在作用,需要进一步调查.
- 需要进行更大规模的研究,以阐明生物标志物的独特贡献,以准高风的疼痛表型.
更多相关视频
07:41Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
3.4K
08:29Author Spotlight: Multiplex Immunohistochemistry for Understanding Immune Regulation by Uterine NK Cells in Pregnancy
Published on: October 25, 2024
1.9K
相关概念视频
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
951
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
01:22Heart Failure VI: Adjunct Therapies
395
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
01:30Heart Failure V: Medical Management
360
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360